Kintsugi Therapeutics

We are a Barcelona based biomedical start-up.

A first-in-class platform

Kintsugi Therapeutics is a preclinical-stage biopharmaceutical Barcelona based company focused on the development of innovative therapies targeting the regulation of endoplasmic reticulum stress for the treatment of liver conditions and other pathologies.

NASH

Non-alcoholic steatohepatitis (NASH) is a common and often clinically silent liver disease that develops as a subgroup of NAFLD characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage.

Discover inhibitors

INHIBITORS

The company’s lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of NASH with ongoing proof of concept.

Meet our team

The team

Meet our team

Carmen Herrero

Carmen Herrero

Co-founder & CEO

Marc Cusachs

Marc Cusachs

Co-founder & COO

Scientific advisory board

Marcin Drag

Marcin Drag

Scientific Advisor

Matias Avila-Zaragoza

Matías Antonio Ávila Zaragozá

Scientific Advisor

Manuel Romero

Manuel Romero-Gómez

Medical Advisor

Manel Puig

Manel Puig-Domingo

Medical Advisor

Board of directors

Carmen Herrero

Carmen Herrero

Board Member

Marc Cusachs

Marc Cusachs

Board Member

Antonio Parente

Antonio Parente

Board Member

Luis Ruiz

Luis Ruiz-Ávila

Board Member

Eduard Golaños

Eduard Goñalons

Board Member

Contact

We’d love to hear from you.

info@kintsugitx.com

linkedin

Arago 60, 08015, Barcelona

Supported by

CDTI logotipo